



Supplementary Material

Antioxidant, Pancreatic Lipase Inhibitory, and Tyrosinase Inhibitory Activities of Extracts of the Invasive Plant *Spartina anglica* (Cord-grass)




Figure S1. LC-ESI-MS data of EA-a.




Figure S2. LC-ESI-MS data of MC-bg.





Figure S3. 1D NMR spectra of compound **1** in CD_3OD .






Figure S4. 1D NMR spectra of compound **2** in CD_3OD .



The ^1H NMR spectrum of **3** (250 MHz)



The ^{13}C NMR spectrum of **3** (62.5 MHz)

Figure S5. 1D NMR spectra of compound **3** in CD_3OD .

qHNMR of EA-a




Figure S6. qHNMR spectrum of compound 1 in EA-a with an internal standard.

qHNMR of MC-bg




Figure S7. qHNMR spectrum of compounds 2 and 3 in MC-bg with an internal standard

Table S1. NMR data of *p*-hydroxybenzaldehyde (**2**) in CD₃OD.

	δ C ¹	δ H ²
1	130.29, C	
2	133.42, CH	7.77 (1H, d, <i>J</i> = 8.7)
3	116.87, CH	6.91 (1H, d, <i>J</i> = 8.7)
4	165.20, C	
5	116.87, CH	6.91 (1H, d, <i>J</i> = 8.7)
6	133.42, CH	7.77 (1H, d, <i>J</i> = 8.7)
7	192.80, CH	9.76 (1H, s)

¹ Measured in CD₃OD with 62.5 MHz. ² Measured in CD₃OD with 250 MHz.

Table S2. NMR data of *N*-*trans*-feruloyltyramine (**3**) in CD₃OD.

	δ C ¹	δ H ²
Feruloyl		
1	131.30, C	
2	111.55, CH	7.12 (1H, d, <i>J</i> = 1.9)
3	149.29, C	
4	149.85, C	
5	116.47, CH	6.79 (1H, d, <i>J</i> = 8.4)
6	123.21, CH	7.00 (1H, dd, <i>J</i> = 8.4, 1.9)
7	142.01, CH	7.43 (1H, d, <i>J</i> = 15.7)
8	118.75, CH	6.40 (1H, d, <i>J</i> = 15.7)
9	169.17, C	
3-OCH ₃	56.39, CH ₃	3.88 (3H, s)
Tyramine		
1'	128.28, C	
2'	130.72, CH	7.06, (1H, d, <i>J</i> = 8.5)
3'	116.26, CH	6.72 (1H, d, <i>J</i> = 8.5)
4'	156.94, C	
5'	116.26, CH	6.72 (1H, d, <i>J</i> = 8.5)
6'	130.72, CH	7.06 (1H, d, <i>J</i> = 8.5)
7'	42.54, CH ₂	2.75 (1H, d, <i>J</i> = 7.4)
8'	35.81, CH ₂	3.47 (1H, d, <i>J</i> = 7.4)

¹ Measured in CD₃OD with 62.5 MHz. ² Measured in CD₃OD with 250 MHz.




Table S3. DPPH radical scavenging activity of 1-3.

Concentration (μ g/mL)	DPPH Radical Scavenging (%)			
	L-Ascorbic Acid	1	2	3
500	- ¹	101.99 \pm 0.37	8.66 \pm 0.30	97.23 \pm 0.33
250	98.14 \pm 0.15	100.78 \pm 1.46	7.28 \pm 0.80	95.51 \pm 0.10
100	97.03 \pm 0.26	89.88 \pm 1.25	3.89 \pm 2.50	93.65 \pm 1.70
50	97.28 \pm 0.27	85.92 \pm 1.27	3.78 \pm 1.40	78.51 \pm 0.06
25	97.50 \pm 0.53	82.94 \pm 0.56	3.61 \pm 1.11	70.53 \pm 1.74
10	98.01 \pm 0.07	51.54 \pm 1.30	4.43 \pm 0.36	63.25 \pm 0.83
5	97.41 \pm 0.46	38.70 \pm 2.24	3.58 \pm 1.79	54.29 \pm 0.30
2	87.36 \pm 2.24	24.91 \pm 0.78	2.73 \pm 2.15	14.90 \pm 1.63
1	45.09 \pm 1.40	11.87 \pm 0.82	2.93 \pm 2.39	0.86 \pm 2.12

¹Not tested.**Table S4.** ABTS radical scavenging activity of 1-3.

Concentration (μ g/mL)	ABTS Radical Scavenging (%)			
	L-Ascorbic Acid	1	2	3
50	99.77 \pm 0.08	66.38 \pm 1.47	8.71 \pm 0.21	82.19 \pm 1.38
25	99.75 \pm 0.06	66.31 \pm 1.84	3.97 \pm 0.43	78.71 \pm 0.06
5	70.41 \pm 0.28	27.97 \pm 4.11	2.03 \pm 0.00	44.18 \pm 2.64

Table S5. Pancreatic lipase inhibition by 1-3.

Concentration (μ g/mL)	Inhibition of Pancreatic Lipase (%)			
	Orlistat	1	2	3
100	- ¹	41.11 \pm 0.01	52.65 \pm 0.00	17.28 \pm 0.02
50	- ¹	37.95 \pm 0.02	42.68 \pm 0.01	16.96 \pm 0.02
25	- ¹	21.17 \pm 0.01	36.64 \pm 0.02	15.87 \pm 0.02
10	- ¹	0.73 \pm 0.01	15.07 \pm 0.01	14.76 \pm 0.01
1.00	54.53 \pm 0.02	- ¹	- ¹	- ¹
0.50	51.17 \pm 0.01	- ¹	- ¹	- ¹
0.25	27.63 \pm 0.01	- ¹	- ¹	- ¹
0.10	22.98 \pm 0.01	- ¹	- ¹	- ¹

¹Not tested.**Table S6.** Spiked qHNMR data of compound 1 in EA-a.

% w/w of Compound 1 in EA-a	Amount of Compound 1 Sample	Spiked Amount of 1	% w/w of Compound 1 in EA-a	Amount of Compound 1 Sample	Amount of Spiked Compound 1 in Spiked Sample (mg)
	(mg)	(mg)		(mg)	
EA-a 1	4.35	0.435		9.35	0.935
EA-a 2	4.76	0.465	0.500	9.79	0.989
EA-a 3	4.83	0.488		9.57	0.967
Average	4.65	0.463	0.500	9.57	0.963
S.D.	0.26	0.027	-	0.22	0.027
C.V.	0.06	0.058	-	0.02	0.028

Table S7. qHNMR data of compounds **2** and **3** in MC-bg.

% w/w of Compound 2 in EA-a sample	Amount of Compound 2 (mg)	% w/w of Compound 3 in EA-a Sample	Amount of Compound 3 (mg)
MC-bg 1	0.87	0.087	4.64
MC-bg 2	0.86	0.086	4.60
MC-bg 3	0.88	0.088	4.58
Average	0.87	0.087	4.61
S.D.	0.01	0.001	0.03
C.V.	0.01	0.011	0.007